LNC PHARMA

LNC PHARMA, a subsidiary of Dongcheng Pharmaceutical, was established in Singapore. On May 2, the company received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational drug 18F-LNC1007 Injection, and Phase I clinical trials are set to commence shortly in Australia. The company’s pipeline product, 18F-LNC1007 Injection, is a novel dual-target radiopharmaceutical diagnostic agent.